Pasireotide diaspartate (SOM-230 diaspartate) is the diaspartate salt of Pasireotide, which is a cyclohexapeptide somatostatin analog. It exhibits unique high-affinity binding to human somatostatin receptors (subtypes sst1/2/3/4/5, pKi=8.2/9.0/9.1/<7.0/9.9 respectively). It is an orphan drug approved for the treatment of Cushing's disease in patients who fail or are ineligible for surgical therapy. It was developed by Novartis. Pasireotide is a somatostatin analogue with a 40-fold increased affinity to somatostatin receptor 5 compared to other somatostatin analogues.

纯度：≥98%

CAS：820232-50-6